Publicaciones en las que colabora con Luis Montuenga Badía (23)

2024

  1. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  3. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  2. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2020

  1. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2018

  1. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients

    Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432

  2. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2017

  1. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer

    Cancer Discovery, Vol. 7, Núm. 12, pp. 1420-1435

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. 524-536

2015

  1. Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations

    BMC Genomics, Vol. 16, Núm. 1

2013

  1. Identificación de marcadores genómicos con valor pronóstico en pacientes diagnosticados de carcinoma de pulmón en estadio temprano mediante microarrays de single nucleotide polymorphisms (SNPs)

    Anales del sistema sanitario de Navarra, Vol. 36, Núm. 1, pp. 167-169

  2. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer

    Journal of the National Cancer Institute, Vol. 105, Núm. 18, pp. 1385-1393

2011

  1. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166

2010

  1. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

    Molecular Cancer, Vol. 9

  2. Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer

    BMC Genomics, Vol. 11, Núm. 1

  3. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression

    Clinical Cancer Research, Vol. 16, Núm. 16, pp. 4113-4125